Clinical trials: Artery Occlusion
Critical Limb Ischemia
The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia
Single phased global, prospective, multicenter clinical trial designed to demonstrate a superior patency rate and acceptable safety in below the knee arteries with lesions treated with the DES BTK Vascular Stent System vs.
- Trial name
- SAVAL (NCT03551496)
- Testing
- Drug Eluting Stent - Below the Knee, Standard PTA Control Arm
- Where
- 42 sites in United States, Belgium and 3 more
- Volunteers
- 201 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
Elixir Medical Clinical Evaluation of the Novolimus-Eluting Coronary Stent System: A Randomized Study "EXCELLA II STUDY"
Randomized Study To evaluate the safety and effectiveness of the Elixir Medical DESyne Novolimus-Eluting Coronary Stent System with Durable Polymer through the assessment of clinical, angiographic and IVUS endpoints as compared…
- Trial name
- NCT00792753
- Testing
- Medtronic Endeavor Coronary Stent System, DESyne BD Novolimus Stent System, DESyne Novolimus Stent System
- Where
- 8 sites in Australia, Belgium and 6 more
- Volunteers
- 360 people
- Sponsor
- Elixir Medical Corporation
Atherosclerosis, Coronary Artery Disease
MARS - Monitored Atherosclerosis Regression Study
The purpose of this study is to determine whether significant alterations in serum lipoproteins as provided by the drug lovastatin can substantially reduce atherosclerosis progression or even induce regression.
- Trial name
- NCT00116870
- Testing
- lovastatin
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- Merck Sharp & Dohme LLC
Coronary Artery Disease (CAD)
A Phase I Study to Evaluate XTR003 in Healthy Chinese Volunteers
18F-FDG PET imaging is now considered the most effective method used in the clinical evaluation of viable myocardium. However, the need for fasting or glucose and insulin loading in the 18F-FDG PET protocol makes it unfavorable…
- Trial name
- NCT05136391
- Testing
- XTR003
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Sinotau Pharmaceutical Group
Peripheral Artery Disease, Vascular Disease
Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients
The purpose of the study is to assess the effect of blood flow to the heart when subjects are treated with ticagrelor (Brilinta) or clopidogrel (antiplatelet drugs that stop the blood from clumping together) in patients with…
- Conditions
- Peripheral Artery Disease, Vascular Disease, Arterial Occlusion Disease, Intermittent Claudication
- Trial name
- PAD (NCT02121288)
- Testing
- Ticagrelor, clopidogrel
- Sponsor
- AstraZeneca
Peripheral Arterial Disease, Acute Limb Ischemia
Pounce™ Thrombectomy System Retrospective Registry
The PROWL registry is an open-label retrospective, multi-center, US study of the Surmodics™ Pounce™ Thrombectomy System for the non-surgical removal of emboli and thrombi in the peripheral arterial vasculature.
- Trial name
- PROWL (NCT05868161)
- Testing
- Pounce Thrombectomy System
- Where
- 9 sites in United States
- Volunteers
- 500 people
- Sponsor
- SurModics, Inc.
Coronary Artery Disease
The Medtronic Endeavor III Drug Eluting Coronary Stent System Clinical Trial
To demonstrate the equivalency in in-segment late lumen loss at 8 months between the Endeavor Drug Eluting Coronary Stent System coated with ABT-578 (10 micrograms/mm) and the Cypher Sirolimus-Eluting Coronary Stent System for…
- Trial name
- ENDEAVOR III (NCT00217256)
- Testing
- Percutaneous Coronary Stenting
- Volunteers
- 436 people
- Sponsor
- Medtronic Vascular
Peripheral Artery Disease
ILLUMENATE Pivotal Post-Approval Study (PAS)
The ILLUMENATE Pivotal PAS is a continued follow-up study which will include 300 subjects from forty-three (43) sites across the United States and Austria previously enrolled in the ILLUMENATE Pivotal pre-market study to evaluate…
- Trial name
- NCT03421561
- Testing
- Stellarex 0.035" OTW Drug-coated Angioplasty Balloon, EverCross™ 0.035 PTA Balloon Catheter
- Where
- 41 sites in United States, Austria
- Volunteers
- 300 people
- Sponsor
- Spectranetics Corporation
Peripheral Arterial Disease, Intermittent Claudication
Efficacy Study of Oral L-Citrulline in Patients Taking Simvastatin With Peripheral Arterial Disease
To prove the combination of L-citrulline with simvastatin leads to greater improvement in the symptoms of peripheral arterial disease (PAD) than simvastatin alone by evaluating oral L- citrulline or placebo against simvastatin…
- Trial name
- NCT00351286
- Testing
- L-citrulline tablets, 1000 mg, Background simvastatin at a stable dose of 40 mg qHS
- Where
- 10 sites in Russia
- Volunteers
- 160 people
- Sponsor
- Angiogenix
Coronary Heart Disease
A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Undergoing Percutaneous Intervention
Study of SB-681323 (a novel p38 MAPkinase inhibitor) in subjects with documented coronary heart disease (CHD) undergoing elective percutaneous coronary intervention (PCI).
- Trial name
- NCT00291902
- Testing
- SB-681323
- Where
- 7 sites in Denmark, Poland
- Volunteers
- 80 people
- Sponsor
- GlaxoSmithKline
Coronary Arteriosclerosis, Hypercholesterolemia
Comparative Atorvastatin Pleiotropic Effects
The primary objective of the study is to evaluate the efficacy of atorvastatin 80 mg daily as compared to atorvastatin 10 mg daily in reducing C-reactive protein levels over a 26-week treatment period in subjects with documented…
- Trial name
- CAP (NCT00163202)
- Testing
- Blood samples, Atorvastatin
- Where
- 74 sites in Canada, Czechia and 5 more
- Volunteers
- 330 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Peripheral Artery Disease
A Study of the SMART Stent in the Treatment SFA Disease.
The main objective of this study is to assess the safety and performance of the sirolimus coated Cordis SMART™ nitinol self expandable stent device and its delivery system in the treatment of obstructive superficial femoral…
- Trial name
- SIROCCO (NCT00232869)
- Testing
- drug-eluting stent, bare-metal stent
- Where
- Germany
- Volunteers
- 93 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
Clinical Evaluation of the CADenceTM System in Detection of Coronary Artery Diseases
The purpose of the study is to evaluate the effectiveness of the CADence system, a non-invasive device, in detecting greater than or equal to 50% coronary stenosis anywhere in the coronary tree.
- Trial name
- CADENCE (NCT01584622)
- Testing
- CADence System
- Where
- 7 sites in United States
- Sponsor
- AUM Cardiovascular, Inc.
Coronary Artery Disease
ST Segment Detection Study
The purpose of ST Detect study is to evaluate whether naturally occurring spontaneous coronary events and exercise induced cardiac ischemia, give rise to detectable changes on intracardiac electrogram (EGM) signals in patients…
- Trial name
- ST Detect (NCT00930969)
- Testing
- ICD
- Where
- 25 sites in United States, Austria and 5 more
- Volunteers
- 175 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Coronary Artery Disease
PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease
The study will be conducted at up to 25 U.S. centers and will be a double-blind randomized parallel group placebo controlled study among subjects with stable coronary artery disease (CAD).
- Trial name
- PLASMA 2 (NCT00525954)
- Testing
- A-002
- Where
- 13 sites in United States
- Volunteers
- 120 people
- Sponsor
- Anthera Pharmaceuticals
Peripheral Artery Disease
A Study Related to the VOYAGER PAD Trial to Learn More About the Target Population for Xarelto in French Patients
This is a study to learn more about French patients who have peripheral artery disease (PAD) and who have had a revascularization procedure.
- Trial name
- PADELTO (NCT04824729)
- Testing
- Lower limb revascularization
- Where
- France
- Volunteers
- 227,613 people
- Sponsor
- Bayer
Peripheral Arterial Disease, Peripheral Arterial Occlusive Disease
VITUS Post-Market Registry
To collect post marketing surveillance data on consecutive patients with peripheral arterial occlusive disease (PAOD) intended to be or treated by the VITUS peripheral drug-coated dilatation catheter when used according to the…
- Trial name
- NCT06832631
- Testing
- Percutaneous Transluminal Angioplasty with a paclitaxel drug-coated balloon
- Where
- 13 sites in Belgium, Germany and 2 more
- Volunteers
- 283 people
- Sponsor
- OrbusNeich
Peripheral Artery Disease
AcoArt Ⅰ / SFA China
The purpose of this study is to determine whether DEB is more effective than common PTA balloon in long-term vessel patency and inhibiting restenosis.
- Trial name
- NCT01850056
- Testing
- drug eluting balloon catheter (trade name: Orchid), common percutaneous transluminal angioplasty balloon catheter (trade name: Admiral)
- Where
- 10 sites in China
- Volunteers
- 200 people
- Sponsor
- Acotec Scientific Co., Ltd
Healthy Subjects, Atherosclerosis
Effect Of Rilapladib (SB-659032) On Platelet Aggregation
The purpose of this study is to compare the effects of repeat doses of SB-659032 with placebo on platelet aggregation in subjects.
- Trial name
- NCT00387257
- Testing
- Rilapladib (SB-659032)
- Where
- Australia
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Coronary Artery Disease (CAD)
A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)
The purpose of this study is to demonstrate that the strength of agreement between single photon emission computed tomography (SPECT) imaging with regadenoson following inadequate exercise stress testing and SPECT imaging with…
- Trial name
- EXERRT (NCT01618669)
- Testing
- Regadenoson, Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
- Where
- 69 sites in United States, Argentina and 2 more
- Volunteers
- 1,147 people
- Sponsor
- Astellas Pharma Global Development, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.